We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials
Summary
This review summarizes immunotherapy strategies for gastric cancer, focusing on PD-L1 expression and immune checkpoint inhibitors (ICIs). Accumulating evidence suggests that targeting the immune response, particularly through ICIs, may improve clinical outcomes in patients with gastric cancer.
Gastric cancer (GC) is the one of the most commonly solid cancer worldwide. Although under the aggressive treatment, the poor clinical outcomes of patients with GCs have not been improved. Current studies emphasized that targeting therapies or immune response-based therapeutic strategy may be a potential approach to improve the clinical outcomes. Moreover, accumulative evidence has reported the increasing expression of PD-L1 expression in GC cells and highlighted its role in the tumor progression. Currently, great development has been established in the immune checkpoint inhibitors (ICIs) and further changed the clinical practice of GC treatment and prognosis. In addition, the combination therapies with targeting therapy or traditional therapies are expected to push the development of immunotherapies. In our present review, we predominantly focus on the biomarkers and molecular profiles for immunotherapies in GCs and highlight the role and administration of ICIs-based immunotherapeutic strategies against the GCs.
Sign in to start a discussion.
More Papers Like This
Meta-analysis of H. pylori and the gut microbiome interactions and clinical outcomes
This meta-analysis identified specific gut microbial signatures associated with H. pylori infection and disease progression, offering predictive models for early diagnosis and risk stratification. The findings support microbiome-based approaches to personalized treatment of H. pylori-associated gastrointestinal disorders.
Characterization of Microplastics in Human Gastric Cancer and Control Tissues and Analysis of Associated Genetic Features
Researchers detected and characterized microplastics in human gastric cancer tissue and adjacent healthy tissue, finding significantly higher microplastic concentrations in cancer tissue, and used transcriptome sequencing to explore potential molecular mechanisms linking microplastic exposure to gastric cancer development.
Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma
Researchers found that a protein called SLC7A11, stabilized by the cancer-driving protein EGFR, blocks cancer cells from being recognized and destroyed by the immune system in nasopharyngeal carcinoma, and showed that the drug sorafenib can reverse this immune evasion by targeting SLC7A11.
Contributing factors common to COVID‑19 and gastrointestinal cancer
This review identifies contributing factors common to COVID-19 vulnerability and gastrointestinal cancer risk, including gut microbiome dysbiosis, dietary patterns, and chronic inflammation, suggesting that immune dysfunction driven by environmental and lifestyle factors underlies susceptibility to both conditions.
Correlation Between Tumor Differentiation and Biomarkers in Hepatocellular Carcinoma: Implications for Early Diagnosis and Treatment
Researchers examined the correlation between tumor differentiation levels and biomarker expression in patients with hepatocellular carcinoma. The study found significant associations between tumor grade and certain biomarker levels, suggesting these markers may have potential value for early diagnosis and treatment planning in liver cancer.